# Cytek Biosciences share price today (Cytek Biosciences, Inc., CTKB)

> Cytek Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. CTKB · Healthcare · Medical Devices · data as of 3 November 2026. Page: https://www.sectoralpha.in/us/stocks/ctkb

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: $5.96 (+52.8% in a year)
- Revenue (Jun 2026): $48.1 M (+5.6% on a year ago)
- Profit (Jun 2026): −$12.2 M
- Operating margin: −29.5% (−6.2 points on a year ago)
- ROE: −20%, FY25
- ROIC: −52.9%, against a 10.3% cost of capital: −63.2 points

Biggest thing to watch: the price has already been rising for 13 weeks, so timing is the risk more than the business. ## What is the Cytek Biosciences share price today? Cytek Biosciences, Inc.'s share price was $5.96 at the close on 3 November 2026. It has been rising for 13 weeks. That is 27.9% above its average price over the last 200 trading days. In the last 52 weeks it traded between $3 and $6, and at that close it sat 94% of the way up from that low. Over the past 13 weeks it has done better than the S&P 500, and it has stayed ahead for 13 weeks in a row. Over the last 5.3 years the share price moved −73% while the S&P 500 moved +72%, so it is behind the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What dividend does Cytek Biosciences pay? Cytek Biosciences, Inc. pays no dividend. In the last 12 reported quarters it declared no dividend per share, so there is no payout history to chart and no yield to show. Companies like this usually keep their earnings in the business, so the cash-flow sections show where that cash goes. ## Which stock lists is Cytek Biosciences on? Cytek Biosciences is not in the Nasdaq 100, the S&P 500 or the Dow Jones 30, and is not on the US tech stocks list. ## Is Cytek Biosciences profitable? Cytek Biosciences, Inc. posted a net loss of $12.2 M in the Jun 2026 quarter. The full FY25 year was a loss of $66.5 M. That loss is 25.3% of the quarter's revenue. The same quarter a year earlier lost $5.6 M. 9 of the last 12 reported quarters were loss-making. ## How much revenue does Cytek Biosciences make, and is it growing? Cytek Biosciences, Inc. reported $48.1 M of revenue in the Jun 2026 quarter, +5.6% on the same quarter a year earlier. That is the 4th quarter in a row with growth on the year before. Over 4 years it has grown 12.0% a year on average. The last full year, FY25, came in at $201 M. The last four reported quarters add to $207 M. FY25 revenue was $201 M, +0.5% on the year before. Recent pace: the last four quarters grew +5.4% on average, against 12.0% a year over the longer run, so this year is growing slower than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +5.4%, against +2.3% a year over the last 8 quarters (accelerating). ## How much of every $100 of sales does Cytek Biosciences keep? Cytek Biosciences, Inc.'s operating margin was −29.5% in the Jun 2026 quarter, 6.2 percentage points lower than the same quarter a year ago. Across 5 years it has been between −20.0% and 7.2%. The latest quarter is below every full year in that period. Why the margin moved: operating margin changed −6.2 percentage points on the year while gross margin changed +0.8 points. So the drop came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Cytek Biosciences' profit turning into cash? Over the last 2 years Cytek Biosciences, Inc.'s operations used more cash than they brought in, so cash conversion was −289%, a gap worth watching. In FY25 its operations used $4.7 M of cash, against −$66.5 M of profit. After $4.1 M of spending on assets, free cash was −$8.8 M: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why: the cash figure is clear, but the day counts behind it are not in our data, so we show it without guessing the reason. What to look at next: the main use of cash is spending on assets. The next section checks what that spending is building. ## Where does Cytek Biosciences' cash go? Cytek Biosciences, Inc. does not report the customer, stock and supplier day counts a cash cycle needs, so this section looks at its spending on assets instead. It spent $12.3 M on assets over the last 3 years. Averaged over those years that is 2.0% of FY25 revenue a year. Nothing is estimated in place of the missing day counts, so no cash-cycle chart is drawn. Spending on assets: $12.3 M over the last 3 years. In short: most of the cash goes on covering the loss, not on new assets; spending on assets is small next to it. ## What is Cytek Biosciences' P/E ratio, and how does it compare with its own history? Cytek Biosciences, Inc. has no P/E right now, because its earnings are negative. The revenue and margin sections are where a turn would show first. Measured against sales instead, the market values Cytek Biosciences, Inc. at 3.8× its FY25 revenue of $201 M. The P/E comes back here once profit turns positive. ## Is the Cytek Biosciences business getting better or worse? Cytek Biosciences, Inc.'s business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 12 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Cytek Biosciences earn on its capital? Cytek Biosciences, Inc. earned a ROE of −20% in FY25. Its return on capital used (ROIC) is 63.2 percentage points below its cost of capital, so growth here does not yet pay for the capital it uses. It comes from a −33.0% net margin and 0.44× asset turnover (sales divided by assets). Why the return is what it is (FY25): a −33.0% net margin × 0.44× asset turnover × 1.35× leverage (assets divided by equity) ≈ −19.6% on equity. The margin does its share; borrowing plays a small part, so this return is earned, not borrowed. The key test, return on capital used minus the cost of capital: −52.9% − 10.3% = −63.2 percentage points. The 10.3% is an estimate of this company's own cost of capital. Read the sign and size of the gap, not the decimals. Negative: growth at these returns loses value until returns improve. The −52.9% ROIC above is the latest reading, as reported. The yearly chart below shows FY25 at −33.8%, and the quarterly chart works out each 12-month window from the quarterly figures, so the readings differ by date, not by method. ## Does Cytek Biosciences have too much debt? Cytek Biosciences, Inc. has total debt of $26.5 M against shareholder equity of $322 M as of Jun 2026, so its debt is 0.08× its equity, which is very little. Year by year, that ratio went from 0.04 in FY22 to 0.07 in FY25. So the returns on this page come from the business, not from borrowed money. ## What is the Cytek Biosciences shareholding pattern? 4.3% of Cytek Biosciences, Inc.'s tradable shares are in short positions, which are bets that the price will fall, so some traders are betting against it. At normal trading volumes, closing those positions would take about 2.7 days. US companies do not publish a quarter-by-quarter list of owners, so this page uses short interest instead. It is a single reading at one point in time; we do not have its history. Why it is at this level: the figure does not say who holds the short positions or why, so we show the level without guessing the story. ## How far is Cytek Biosciences from balance-sheet trouble? For Cytek Biosciences, Inc., the Z-score is 3.15. A Z-score above about 3 is safe and below about 1.8 signals danger, so this is well clear of danger. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. Why it matters: a Z-score of 3.15 is well clear of the danger zone, so the balance sheet is not the risk here. ## How does Cytek Biosciences rank in its industry? There is no score against its industry: Cytek Biosciences, Inc. is not among the largest members shown in this industry comparison for Medical Devices. The score ranks a company within its industry: each measure is scored against the other members. Without that group there is no score, so none is shown. ## Which companies is Cytek Biosciences compared with? No sector comparison is shown here, not among the largest members shown in this industry comparison. ## Which companies are close to Cytek Biosciences in size? Cytek Biosciences is the 49th largest of 75 Medical Devices companies on Sector Alpha by market value (scores of 3 November 2026). Just above it: OrthoPediatrics Corp., InMode and Varex Imaging Corporation. Just below it: Pacific Biosciences of California, Inc., Tactile Systems Technology, Inc. and Sight Sciences, Inc. ### Medical Devices companies close in size

1. [OrthoPediatrics Corp.](https://www.sectoralpha.in/us/stocks/kids) $820 million
2. [InMode Ltd.](https://www.sectoralpha.in/us/stocks/inmd) $809 million
3. [Varex Imaging Corporation](https://www.sectoralpha.in/us/stocks/vrex) $781 million
4. Cytek Biosciences, Inc. $775 million
5. [Pacific Biosciences of California, Inc.](https://www.sectoralpha.in/us/stocks/pacb) $758 million
6. [Tactile Systems Technology, Inc.](https://www.sectoralpha.in/us/stocks/tcmd) $561 million
7. [Sight Sciences, Inc.](https://www.sectoralpha.in/us/stocks/sght) $519 million

[All 75 Medical Devices companies, largest first](https://www.sectoralpha.in/us/sectors/medical-devices#all-companies)

### Companies close in size in other industries

1. [Universal Logistics Holdings, Inc.](https://www.sectoralpha.in/us/stocks/ulh) $753 million · Trucking
2. [Peoples Financial Services Corp.](https://www.sectoralpha.in/us/stocks/pfis) $750 million · Banks - Regional
3. Cytek Biosciences, Inc. $750 million
4. [Climb Global Solutions, Inc.](https://www.sectoralpha.in/us/stocks/clmb) $750 million · Electronics & Computer Distribution
5. [Cresud Sociedad Anónima, Comercial, Inmobiliaria, Financiera y Agropecuaria](https://www.sectoralpha.in/us/stocks/cresy) $747 million · Conglomerates

## What else do people ask about Cytek Biosciences? ### What were Cytek Biosciences's latest quarterly results? Cytek Biosciences, Inc. reported revenue of $48.1 M and a net loss of $12.2 M for the Jun 2026 quarter. Earnings per share were −$0.09. The operating margin was −29.5%, 6.2 percentage points lower than a year earlier (as of 3 November 2026). ### What is Cytek Biosciences's market cap? Cytek Biosciences, Inc.'s market capitalisation is $775 M at a stock price of $5.96. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Cytek Biosciences performing? Cytek Biosciences, Inc.'s share price has been rising for 13 weeks. Over the past 13 weeks it has done better than the S&P 500, for 13 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Cytek Biosciences's stock price go up? This page does not forecast Cytek Biosciences, Inc.'s stock price. What it shows instead: the stock price is $5.96, and it has been rising for 13 weeks. Nobody can reliably say which way a price will move, and this site does not try (as of 3 November 2026). ### Where is Cytek Biosciences in its business cycle? Cytek Biosciences, Inc.'s FY25 operating margin was −20.0%, against a 5-year range of −20.0% to 7.2%: the low end of its own range, which is often where recoveries start. The latest quarter was −29.5%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Cytek Biosciences story? Biggest thing to watch: the price has already been rising for 13 weeks, so timing is the risk more than the business. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Cytek Biosciences a stock worth studying right now? What the numbers show: Cytek Biosciences, Inc.'s share price, valuation and earnings point in different directions. The next one or two quarters should make it clearer. The main open question: the next one or two quarters of results. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). This is research, not advice. We’re not SEBI-registered.